Long Term Management of Glucose and Weight in Type 2 Diabetes Using Escherichia coli Nissle 1917 Expressing CTB-IGF1 and CTB-amylin
By Mahsa Jalili
Current therapeutic options for diabetes mellitus are feeble in long term management of blood glucose, which can result in many serious complications. Recent studies illustrate that the intestinal microflora is a feasible vehicle to deliver the target hormones to the liver and a cost-effective option for in-situ gene therapy. We hypothesized that recombinant probiotics of Escherichia coli Nissle 1917 expressing the CTB-IGF1 and CTB-amylin hybrid proteins under the control of the glucose sensitive ompC promoter may be a long-term novel strategy for management of glucose homeostasis and weight in patients with type 2 diabetes.